The drug industry and the obstacles for timely flow of information and their effects on the public health;La industria farmacéutica y los obstáculos para el flujo oportuno de información: Consecuencias para la salud pública

Revista Cubana de Salud Publica

Volumn 37, Issue SUPPL. 5, 2011, Pages 631-643

  Ayçaguer, Luis Carlos Silva ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 82055189740     PISSN: 08643466     EISSN: 15613127     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. De Angelis CD, Fontanarosa PB. The adverse effects of industry influence. JAMA. 2008; 299(15):1833-5.
2. Good CB, Kelley CL. The Vioxx debacle revisited. Am J Med. 2005;118(9):1055-6.
3. Burton B. Diabetes expert accuses drug company of "intimidation". BMJ. 2007;335(7630):1113.
4. Simth R. Medical journals and pharmaceutical companies: uneasy bedfellows. BMJ. 2003;326(7400):1202-5.
5. The PLoS Medicine Editors. Ghostwriting: the dirty little secret of medical publishing that just got bigger. PLoS Med. 2099;6(9):e1000156. doi:10.1371/journal.pmed1000156.
6. Angell M. The truth about the drug companies: how they deceive us and what to do about it. New York: Random House; 2005.
7. Smith R. The trouble with medical journals. London: Royal Society of Medicine Press; 2006.
8. Blech J. Los inventores de enfermedades. Cómo nos convierten en pacientes. Barcelona: estino; 2005
9. Mirowski P, Van Horn R. The Contract Research Organization and the commercialization of scientific research. Soc Stud Sci. 2005;35(4):503-48.
10. Silva LC. Los laberintos de la investigación biomédica. En defensa de la racionalidad para la ciencia del siglo XXI. Madrid: Editorial Díaz de Santos; 2009.
11. Chalmers I. From optimism to disillusion about commitment to transparency in the medico-industrial complex. J R Soc Med 2006;99:337-41.
12. Davidoff F, DeAngelis CD, Drazen JM y col. Sponsorship, authorship, and accountability. N Engl J Med. 2001;345:825-6.
13. Bodenheimer T. Uneasy alliance -clinical investigators and the pharmaceutical industry. N Engl J Med 2000;342:1539-44.
14. Brownlee, S. Doctors Without Borders: Why you can't trust medical journals any-more. The Washintton Monthly, 2004 April 04.
15. Michaels D. Doubt is their product. How industry's assault on science threatens your health. Oxford: Oxford University Press; 2008.
16. Relman AS. Dealing with conflicts of interests. N Engl J Med. 1984;310(18):1182-3.
17. Lexchin J, Bero L, Djubegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326(7400):1167-70.
18. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA. 2003;290(23):921-8.
19. Bekelman JE, LI Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289(4):454-65.
20. Bourgeois F, Murthy S, Mandl KD. Drug trials funded by industry more likely to publish favorable results, Ann Intern Med. 2010;153:158-66.
21. Smith R. Conflict of interest and the BMJ. Time to take it more seriously. BMJ. 1994;308(6920):4-5.
22. Lurie P, Almeida CM, Stine N, Stine AR, Wolfe SM. Financial conflict of interest disclosure and voting patterns at Food and Drug Administration drug advisory committee meetings. JAMA. 2006;295(16):1921-8.
23. Jetter A. Strong Medicine: What's Ailing the FDA? Reader's Digest. 2008; Abril:105.
24. Cohen D. Rosiglitazone what went wrong. BMJ. 2010;341:c4848.
25. Salas S, Russo M. Transparencia en la investigación biomédica: A propósito de los riesgos asociados al uso de Avandia. Rev Med Chile 2010;138:1197-200.
26. Nissen SE, Wolski K. (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-71
27. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP et al. Rosiglitazone evaluated for cardiac outcomes -an interim analysis. N Engl J Med. 2007;357(1):28-38
28. Committee on Finance United States Senate. The intimidation of Dr John Buse and the diabetes drug Avandia [Internet]. [citado 5 Nov 2007]. Disponible en: http://www.senate.gov/~finance/press/Bpress/2007press/prb111507a.pdf
29. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125-35.
30. Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia. Prepared by the staff of the Committee on Finance, United States Senate, Max Baucus, Chairman, Chuck Grassley, Ranking Member Avandia [Internet]. [citado 27 May 2011]. Disponible en: http://finance.senate.gov/press/Gpress/2010/prg022010a.pdf
31. Harris G. Research ties diabetes drug to heart woes. New York Times; 2010;20 de febrero.
32. Nissen SE. Setting the RECORD Straight. JAMA. 2010;303:1194-5
33. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010;170(14):1191-201.
34. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010;304(4):411-8.
35. Drazen JM, Wood AJJ. Don't mess with the DSMB. N Engl J Med. 2010;363(5):477-8.
36. Harris G. Diabetes drug maker hid test data, files indicate. New York Times, 2010 13 de julio.
37. Sampedro J. Glaxo ocultó los riesgos de su fármaco estrella contra la diabetes. El País, 2010 14 de julio.
38. Mundy A. Cardiologist Steven Nissen's reaction to FDA decision on avandia. The Wall Street Journal, 2010; 23 de septiembre.
39. Blind E, Dunder K, de Graeff PA, Abadie E. Rosiglitazone: a European regulatory perspective. Diabetologia. 2011;54(2):213-8.
40. Proyecto ACSI [Internet]. [citado 20 May 2011]. Disponible en: http://www.cgcom.org/tecnologica/acsi.
41. Excelencia clínica [Internet]. [citado 20 May 2011]. Disponible en: http://excelenciaclinica.net
42. Carr N. The big switch, rewiring the world from Edison to Google. New York: Norton and Company; 2008